Literature DB >> 10361224

Studies of the mechanism of cytolysis by tumour-infiltrating lymphocytes.

M Hishii1, J T Kurnick, T Ramirez-Montagut, F Pandolfi.   

Abstract

In order to determine the mechanism of tumour destruction by tumour-infiltrating lymphocytes (TIL), we examined the ability of both CD4+ and CD8+ effector TIL, and TIL clones, to manifest granzyme-mediated and Fas-mediated destruction of tumour targets. In many in vitro studies TIL have been shown to manifest anti-tumour reactivity, yet many tumours escape immunological destruction. To investigate the role of Fas expression and the concomitant sensitivity to the inducibility of apoptotic death, we derived TIL from four melanomas and one glioma. The glioma, and all but one of the melanomas, expressed Fas, but Fas-mediated apoptosis could only be detected if the targets were treated with cyclohexamide. The melanomas and the glioma all expressed detectable cytoplasmic Bcl-2 protein, known to exert anti-apoptotic activity. Lysis of tumours by CD8-enriched cultures and CD8+ clones was Ca2+-dependent and could not be modified by an anti-Fas MoAb. In CD4-enriched cultures or CD4+ clones with cytotoxic potential against tumour cells, cytotoxicity was also Ca2+-dependent. As Ca2+-dependent cytotoxicity is usually the result of secretion of perforin/granzyme-B, we investigated the presence of perforin in cytotoxic CD4+ clones and demonstrated the presence of granular deposits of this enzyme in some of the CD4+ clones. Although an anti-Fas MoAb did not block the lysis of melanoma targets by CD4+ clones, the examination of Fas-dependent targets demonstrated that these clones also had the potential to kill by the Fas/Fas ligand system. These data suggest that the predominant mechanism in tumour killing by TIL appears to be perforin-granzyme-dependent, and that the solid tumour cell lines we studied are less susceptible to Fas-mediated apoptosis. As non-apoptotic pathways may enhance tumour immunogenicity, exploitation of the perforin-granzyme-dependent cytotoxic T lymphocyte (CTL) pathways may be important for achieving successful anti-tumour responses.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10361224      PMCID: PMC1905310          DOI: 10.1046/j.1365-2249.1999.00879.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  60 in total

1.  Functional characterization of T lymphocytes propagated from human lung carcinomas.

Authors:  J T Kurnick; R L Kradin; R Blumberg; E E Schneeberger; L A Boyle
Journal:  Clin Immunol Immunopathol       Date:  1986-03

2.  Characterization of the CD4+ and CD8+ tumor infiltrating lymphocytes propagated with bispecific monoclonal antibodies.

Authors:  J T Wong; C E Pinto; J D Gifford; J T Kurnick; R L Kradin
Journal:  J Immunol       Date:  1989-11-15       Impact factor: 5.422

3.  Model predicting survival in stage I melanoma based on tumor progression.

Authors:  W H Clark; D E Elder; D Guerry; L E Braitman; B J Trock; D Schultz; M Synnestvedt; A C Halpern
Journal:  J Natl Cancer Inst       Date:  1989-12-20       Impact factor: 13.506

4.  Tumour-infiltrating lymphocytes and interleukin-2 in treatment of advanced cancer.

Authors:  R L Kradin; J T Kurnick; D S Lazarus; F I Preffer; S M Dubinett; C E Pinto; J Gifford; E Davidson; B Grove; R J Callahan
Journal:  Lancet       Date:  1989-03-18       Impact factor: 79.321

5.  Clonal and frequency analyses of tumor-infiltrating T lymphocytes from human solid tumors.

Authors:  S Miescher; T L Whiteside; L Moretta; V von Fliedner
Journal:  J Immunol       Date:  1987-06-01       Impact factor: 5.422

6.  Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report.

Authors:  S A Rosenberg; B S Packard; P M Aebersold; D Solomon; S L Topalian; S T Toy; P Simon; M T Lotze; J C Yang; C A Seipp
Journal:  N Engl J Med       Date:  1988-12-22       Impact factor: 91.245

7.  A multivariate analysis of prognostic factors for melanoma patients with lesions greater than or equal to 3.65 mm in thickness. The importance of revealing alternative Cox models.

Authors:  C L Day; R A Lew; M C Mihm; A J Sober; M N Harris; A W Kopf; T B Fitzpatrick; T J Harrist; F M Golomb; A Postel; P Hennessey; S L Gumport; J W Raker; R A Malt; A B Cosimi; W C Wood; D F Roses; F Gorstein; D Rigel; R J Friedman; M M Mintzis; R W Grier
Journal:  Ann Surg       Date:  1982-01       Impact factor: 12.969

8.  Metabolic inhibitors distinguish cytolytic activity of CD4 and CD8 clones.

Authors:  P Strack; C Martin; S Saito; R H Dekruyff; S T Ju
Journal:  Eur J Immunol       Date:  1990-01       Impact factor: 5.532

9.  Clonal analysis of cytotoxic and regulatory T cell responses against human melanoma.

Authors:  B Mukherji; A Guha; N G Chakraborty; M Sivanandham; A L Nashed; J R Sporn; M T Ergin
Journal:  J Exp Med       Date:  1989-06-01       Impact factor: 14.307

10.  Autologous tumor-specific cytotoxic T lymphocytes in the infiltrate of human metastatic melanomas. Activation by interleukin 2 and autologous tumor cells, and involvement of the T cell receptor.

Authors:  K Itoh; C D Platsoucas; C M Balch
Journal:  J Exp Med       Date:  1988-10-01       Impact factor: 14.307

View more
  10 in total

1.  Pathogenesis of herpes simplex virus type 1-induced corneal inflammation in perforin-deficient mice.

Authors:  E Chang; L Galle; D Maggs; D M Estes; W J Mitchell
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

2.  Activated cytotoxic lymphocytes promote tumor progression by increasing the ability of 3LL tumor cells to mediate MDSC chemoattraction via Fas signaling.

Authors:  Fei Yang; Yinxiang Wei; Zhijian Cai; Lei Yu; Lingling Jiang; Chengyan Zhang; Huanmiao Yan; Qingqing Wang; Xuetao Cao; Tingbo Liang; Jianli Wang
Journal:  Cell Mol Immunol       Date:  2014-04-28       Impact factor: 11.530

3.  In vivo photolabeling of tumor-infiltrating cells reveals highly regulated egress of T-cell subsets from tumors.

Authors:  Tommaso Torcellan; Henry R Hampton; Jacqueline Bailey; Michio Tomura; Robert Brink; Tatyana Chtanova
Journal:  Proc Natl Acad Sci U S A       Date:  2017-05-15       Impact factor: 11.205

4.  Ex-vivo analysis of CD8+ T cells infiltrating colorectal tumors identifies a major effector-memory subset with low perforin content.

Authors:  Sheng-Wei Ye; Yu Wang; Danila Valmori; Maha Ayyoub; Yan Han; Xiao-Lan Xu; Ai-Lian Zhao; Li Qu; Sacha Gnjatic; Gerd Ritter; Lloyd J Old; Jin Gu
Journal:  J Clin Immunol       Date:  2006-09-12       Impact factor: 8.317

5.  Mutations in the HLA class II genes leading to loss of expression of HLA-DR and HLA-DQ in diffuse large B-cell lymphoma.

Authors:  Ekaterina S Jordanova; Katja Philippo; Marius J Giphart; Ed Schuuring; Philip M Kluin
Journal:  Immunogenetics       Date:  2003-05-17       Impact factor: 2.846

6.  Ectopic T-bet expression licenses dendritic cells for IL-12-independent priming of type 1 T cells in vitro.

Authors:  Michael W Lipscomb; Lu Chen; Jennifer L Taylor; Christina Goldbach; Simon C Watkins; Pawel Kalinski; Lisa H Butterfield; Amy K Wesa; Walter J Storkus
Journal:  J Immunol       Date:  2009-11-13       Impact factor: 5.422

Review 7.  The immune response to tumors as a tool toward immunotherapy.

Authors:  F Pandolfi; R Cianci; D Pagliari; F Casciano; C Bagalà; A Astone; R Landolfi; C Barone
Journal:  Clin Dev Immunol       Date:  2011-12-05

8.  Heat shock protein-90 inhibitors enhance antigen expression on melanomas and increase T cell recognition of tumor cells.

Authors:  Timothy J Haggerty; Ian S Dunn; Lenora B Rose; Estelle E Newton; Franco Pandolfi; James T Kurnick
Journal:  PLoS One       Date:  2014-12-12       Impact factor: 3.240

9.  Comparative investigation of the effects of specific antigen‑sensitized DC‑CIK and DC‑CTL cells against B16 melanoma tumor cells.

Authors:  Peng-Tao Ren; Yuan Zhang
Journal:  Mol Med Rep       Date:  2017-02-07       Impact factor: 2.952

10.  Tissue-infiltrating lymphocytes analysis reveals large modifications of the duodenal "immunological niche" in coeliac disease after gluten-free diet.

Authors:  Rossella Cianci; Giovanni Cammarota; Giovanni Frisullo; Danilo Pagliari; Gianluca Ianiro; Maurizio Martini; Simona Frosali; Domenico Plantone; Valentina Damato; Fabio Casciano; Raffaele Landolfi; Anna Paola Batocchi; Franco Pandolfi
Journal:  Clin Transl Gastroenterol       Date:  2012-12-13       Impact factor: 4.488

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.